May 2026—The Diagnostic Medicine Consortium and Virchow Medical have formed a partnership aimed at expanding longitudinal, evidence-based cancer therapy to more patients. The partnership will leverage Virchow’s Crow’s Nest Biopsy Catchment system and Virchow Vault Liquid Specimen Biorepository to increase the yield of high-quality biospecimens.
DMC is building a patient consent-driven data resource infrastructure to more fully realize the predictive value of laboratory diagnostics, including existing biomarkers for cancer diagnostics and therapeutics, and broaden access to digital pathology assets. This infrastructure will support the development of AI algorithms appropriately validated for the intended patient populations. Virchow is developing a novel biospecimen infrastructure sourced from cells recovered from used biopsy needles that would otherwise have been discarded as medical waste. Together, the two organizations will offer providers and researchers an array of deidentified tumor mutation data with associated metadata.
Virchow Medical, 833-424-6779